ANI PHARMACEUTICALS INC
ANIPNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $67.14 β $87.76
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 22.7M
- Next Earnings
- 2027-02-26
Fundamentals Snapshot
- Annual Revenue
- $883M
- Last Q Revenue
- $291M
- P/E Ratio
- 13.2
- P/S Ratio
- 1.5x
- EPS (TTM)
- $5.51
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +9.2%
ANI PHARMACEUTICALS INC
ANIPAbout ANI PHARMACEUTICALS INC
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

ANI Pharmaceuticals to Present at Upcoming December Investor Conference
PRINCETON, N.J., Nov. 19, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with members of the Compa

Here's Why ANI Pharmaceuticals (ANIP) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ANI Pharmaceuticals, Inc. $ANIP Stock Acquired by Aberdeen Group plc
Aberdeen Group plc boosted its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) by 23.0% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The in

ANI Pharmaceuticals, Inc. (ANIP) Q3 2026 Earnings Call Transcript
ANI Pharmaceuticals, Inc. ( ANIP ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Irina Rivkind Koffler - Vice President of Investor Relations Nikhil Lalwani - President, CEO & Director Mary Pao

ANI Pharmaceuticals Q3 Earnings Call Highlights
ANI Pharmaceuticals NASDAQ: ANIP reported 28% revenue growth for the third quarter of 2026 and announced an offer to acquire Egetis Therapeutics for $560 million in equity value, while lowering its full-year sales outloo

ANI (ANIP) Reports Q3 Earnings: What Key Metrics Have to Say
The headline numbers for ANI (ANIP) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago a